Trial · NCT03399370
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 510 | Inclisiran | -56.34 | 95% Confidence Interval -58.35 to -54.34 | percent change | |
| Percentage Change in LDL-C From Baseline to Day 510 | Placebo | 1.30 | 95% Confidence Interval -1.24 to 3.83 | percent change | |
| Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Inclisiran | -51.27 | 95% Confidence Interval -53.00 to -49.54 | percent change | |
| Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Placebo | 2.51 | 95% Confidence Interval 0.77 to 4.25 | percent change | |
| Absolute Change in LDL-C From Baseline to Day 510 | Inclisiran | -56.18 | 95% Confidence Interval -58.47 to -53.90 | mg/dL | |
| Absolute Change in LDL-C From Baseline to Day 510 | Placebo | -2.06 | 95% Confidence Interval -4.36 to 0.24 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Inclisiran | -53.66 | 95% Confidence Interval -55.41 to -51.92 | mg/dL | |
| Time-adjusted Absolute Change in LDL-C From Baseline After Day 90 and up to Day 540 | Placebo | -0.39 | 95% Confidence Interval -2.14 to 1.37 | mg/dL | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Inclisiran | -69.78 | 95% Confidence Interval -73.88 to -65.67 | percent change | |
| Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 510 | Placebo | 13.52 | 95% Confidence Interval 9.28 to 17.77 | percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Inclisiran | -33.56 | 95% Confidence Interval -35.09 to -32.03 | percent change | |
| Percentage Change in Total Cholesterol From Baseline to Day 510 | Placebo | -0.42 | 95% Confidence Interval -1.95 to 1.11 | percent change | |
| Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510 | Inclisiran | -44.81 | 95% Confidence Interval -46.52 to -43.10 | percent change | |
| Percentage Change in Apolipoprotein B (ApoB) From Baseline to Day 510 | Placebo | -1.72 | 95% Confidence Interval -3.46 to 0.02 | percent change | |
| Percentage Change in Non-HDL-C From Baseline to Day 510 | Inclisiran | -47.41 | 95% Confidence Interval -49.44 to -45.38 | percent change | |
| Percentage Change in Non-HDL-C From Baseline to Day 510 | Placebo | -0.05 | 95% Confidence Interval -2.08 to 1.99 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03399370/results